PURPOSE: To evaluate the feasibility of delivering conformal radiotherapy (RT) and concurrent chemotherapy without a mandatory break in patients with anal canal carcinoma. METHODS AND MATERIALS: Thirty patients with T2-T4 tumors were treated with a combination of 54 Gy in 30 fractions and two cycles of 5-fluorouracil and mitomycin C. Dose-volume histograms were obtained for bone marrow, small bowel, and skin to compare the conventional technique using the Radiation Therapy Oncology Group standard with our conformal technique. RESULTS: The mean dose ratio of the conventional compared with the conformal technique for bone marrow, small bowel, and skin was, respectively, 2.1-2.7, 3.0, and 2.0, in favor of the conformal technique. All patients completed their treatment without a treatment break. An incidence of Grade 3 toxicity for bone marrow, bowel, and skin of 13.3%, 3.3%, and 20%, respectively, was observed. With a median follow-up of 33 months, a 4-year local recurrence-free survival rate of 91% was observed. CONCLUSION: The results of this study have shown that conformal RT leads to a well-tolerated treatment. The treatment time is shortened to 6 weeks. A significant decrease in the acute toxicity rate suggests that by decreasing the "volume factor," conformal RT improves the therapeutic index in patients treated with combined chemotherapy and RT.
PURPOSE: To evaluate the feasibility of delivering conformal radiotherapy (RT) and concurrent chemotherapy without a mandatory break in patients with anal canal carcinoma. METHODS AND MATERIALS: Thirty patients with T2-T4 tumors were treated with a combination of 54 Gy in 30 fractions and two cycles of 5-fluorouracil and mitomycin C. Dose-volume histograms were obtained for bone marrow, small bowel, and skin to compare the conventional technique using the Radiation Therapy Oncology Group standard with our conformal technique. RESULTS: The mean dose ratio of the conventional compared with the conformal technique for bone marrow, small bowel, and skin was, respectively, 2.1-2.7, 3.0, and 2.0, in favor of the conformal technique. All patients completed their treatment without a treatment break. An incidence of Grade 3 toxicity for bone marrow, bowel, and skin of 13.3%, 3.3%, and 20%, respectively, was observed. With a median follow-up of 33 months, a 4-year local recurrence-free survival rate of 91% was observed. CONCLUSION: The results of this study have shown that conformal RT leads to a well-tolerated treatment. The treatment time is shortened to 6 weeks. A significant decrease in the acute toxicity rate suggests that by decreasing the "volume factor," conformal RT improves the therapeutic index in patients treated with combined chemotherapy and RT.
Authors: V Dell'Acqua; J Kobiela; F Kraja; M C Leonardi; A Surgo; M A Zerella; S Arculeo; C Fodor; R Ricotti; M G Zampino; S Ravenda; G Spinoglio; R Biffi; A Bazani; R Luraschi; S Vigorito; P Spychalski; R Orecchia; R Glynne-Jones; B A Jereczek-Fossa Journal: Med Oncol Date: 2018-03-28 Impact factor: 3.064
Authors: Christoph Oehler; Sawyna Provencher; David Donath; Jean-Paul Bahary; Urs M Lütolf; I Frank Ciernik Journal: Radiat Oncol Date: 2010-05-13 Impact factor: 3.481
Authors: Stefan Janssen; Jürgen Meier zu Eissen; Gerd Kolbert; Michael Bremer; Johann Hinrich Karstens; Andreas Meyer Journal: Int J Colorectal Dis Date: 2009-08-01 Impact factor: 2.571
Authors: Maria G Zampino; Elena Magni; Maria C Leonardi; Luigi Santoro; Elena Petazzi; Cristiana Fodor; Giuseppe Petralia; Cristina Trovato; Franco Nolè; Roberto Orecchia Journal: BMC Cancer Date: 2011-02-03 Impact factor: 4.430